Can a blood test guide better cancer treatment after surgery?

NCT ID NCT06914011

Not yet recruiting Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without additional treatment. The goal is to see if this personalized approach improves the chance of staying cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (a type of immunotherapy) combined with chemotherapy (paclitaxel and carboplatin) and radiation
What this could lead to: If successful, this approach could help doctors decide who needs extra treatment after surgery, potentially reducing the chance of cancer returning in patients with esophageal cancer.
What could go wrong: This is an early-stage Phase 3 trial with only 172 participants, so results may not apply to everyone. The combination therapy also carries risks like side effects from chemotherapy and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.